<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: <z:hpo ids='HP_0001945'>Fever</z:hpo> of unknown origin (FUO) in children presents a diagnostic challenge </plain></SENT>
<SENT sid="1" pm="."><plain>The differential diagnosis includes systemic-<z:hpo ids='HP_0003674'>onset</z:hpo> juvenile idiopathic <z:hpo ids='HP_0001369'>arthritis</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e>), an autoinflammatory syndrome associated with activation of phagocytic cells that, at presentation, is difficult to differentiate from severe <z:e sem="disease" ids="C0243026" disease_type="Disease or Syndrome" abbrv="">systemic infections</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to investigate whether serum concentrations of the phagocytic proinflammatory protein S100A12 may help in deciding whether to treat patients with FUO with antibiotics or <z:chebi fb="1" ids="35705">immunosuppressive agents</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Serum samples were obtained from 45 healthy control subjects and from 240 patients (60 with systemic-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e>, 17 with familial Mediterranean <z:hpo ids='HP_0001945'>fever</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e>], 18 with <z:hpo ids='HP_0003623'>neonatal-onset</z:hpo> multisystem <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disease</z:e> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e>], 17 with <z:e sem="disease" ids="C0268390" disease_type="Disease or Syndrome" abbrv="">Muckle-Wells syndrome</z:e> [MWS], 40 with <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> [ALL], 5 with <z:hpo ids='HP_0004808'>acute myeloblastic leukemia</z:hpo> [<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>], and 83 with <z:e sem="disease" ids="C0243026" disease_type="Disease or Syndrome" abbrv="">systemic infections</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> samples were collected at the time of presentation, before the initiation of any treatment, and concentrations of S100A12 were determined by enzyme-linked immunosorbent assay </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The mean +/- 95% confidence interval serum levels of S100A12 were as follows: in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e>, 7,190 +/- 2,690 ng/ml; in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e>, 6,720 +/- 4,960 ng/ml; in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NOMID</z:e>, 720 +/- 450 ng/ml; in patients with MWS, 150 +/- 60 ng/ml; in patients with <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, 470 +/- 160 ng/ml; in patients with ALL, 130 +/- 80 ng/ml; in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 45 +/- 60 ng/ml; in healthy control subjects, 50 +/- 10 ng/ml </plain></SENT>
<SENT sid="6" pm="."><plain>The sensitivity and specificity of S100A12 to distinguish between systemic-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e> and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> were 66% and 94%, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: S100A12, a marker of granulocyte activation, is highly overexpressed in patients with systemic-<z:hpo ids='HP_0003674'>onset</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JIA</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">FMF</z:e>, which may point to as-yet unknown common inflammatory mechanisms in these diseases </plain></SENT>
<SENT sid="8" pm="."><plain>The measurement of S100A12 serum levels may provide a valuable diagnostic tool in the evaluation of FUO </plain></SENT>
</text></document>